雷特格韦相关化合物E(USP) | 1193687-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 雷特格韦相关化合物E(USP)
• 中文别名: 4-去氟雷特格韦；雷特格韦杂质1
• 英文名称: raltegravir
• 英文别名: 4-Defluoro raltegravir；N-[2-[4-(benzylcarbamoyl)-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
• CAS: 1193687-87-4
• 化学式: C₂₀H₂₂N₆O₅
• 分子量: 426.432
• InChiKey: COAAUZDDPLHEFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  在 N-甲基吗啉 、 甲烷磺酸 、 10% Pd/C 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 55.0 ℃ 、200.0 kPa 条件下， 反应 1.0h， 生成 雷特格韦相关化合物E(USP)
  参考文献：
  名称：

  Identification, Synthesis, and Strategy For Minimization of Potential Impurities Observed In Raltegravir Potassium Drug Substance

  摘要：

  Multiple sources of anticipated degradation and process impurities of raltegravir potassium drug substance observed during the laboratory optimization and later during its bulk synthesis are described in this article. The impurities were monitored by UPLC, and their structures are tentatively assigned on the basis of fragmentation patterns in LC-MS and NMR spectroscopy. Most of the impurities are synthesized, and their assigned constitutions were confirmed by co-injection in UPLC. In addition to the formation, synthesis, and characterization, strategy for minimizing these impurities to the level accepted by ICH is also described. We feel that our study will be helpful to the generic industry for obtaining chemically pure raltegravir potassium.

  DOI：

  10.1021/op300077m